Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001600620-25-000049
Filing Date
2025-05-12
Accepted
2025-05-12 06:05:39
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q auph-20250331.htm   iXBRL 10-Q 779218
2 EX-31.1 auph-2025q1exx311.htm EX-31.1 10866
3 EX-31.2 auph-2025q1exx312.htm EX-31.2 11008
4 EX-32.1 auph-2025q1exx321.htm EX-32.1 5334
5 EX-32.2 auph-2025q1exx322.htm EX-32.2 5342
  Complete submission text file 0001600620-25-000049.txt   4922914

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20250331.xsd EX-101.SCH 29758
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT auph-20250331_cal.xml EX-101.CAL 68891
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT auph-20250331_def.xml EX-101.DEF 125343
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20250331_lab.xml EX-101.LAB 511147
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20250331_pre.xml EX-101.PRE 331903
66 EXTRACTED XBRL INSTANCE DOCUMENT auph-20250331_htm.xml XML 621359
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36421 | Film No.: 25932430
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)